Ono Pharmaceutical has partnered with Aitia to use causal AI 'digital twins' to identify new drug targets for hard-to-treat neurological diseases, joining a wave of 2026 pharma-AI deals betting that modeling cause and effect — not just correlation — can finally move the needle on brain disease drug discovery.
A new market analysis shows AI-assisted pathology moving from pilot projects to routine clinical use, spotlighting PathAI's $165 million funding round and its expanded Labcorp partnership — even as independent clinical-outcome trials won't report results until 2029.
Leica Biosystems announced August 11, 2026 it won FDA clearance for what it calls the first standalone AI-assisted quality control tool for digital pathology slide scanning, aimed at catching scanning defects before they corrupt downstream AI diagnostics.
A WHO Europe forum on September 1, 2026 argued that health AI progress should be judged by the strength of governance frameworks rather than deployment speed, building on a 2025 dialogue that surveyed experts from 105 countries.
Advocate Health is deploying AI startup Lind's platform to automatically screen cancer patients for clinical trial eligibility, aiming to fix a system in which only about 5% of eligible patients nationally ever enroll in a trial.
A randomized trial of an AI tool co-developed by Mayo Clinic and Bayesian Health found earlier palliative care referrals cut 90-day hospital readmissions by 28%, offering rare outcome-level proof for a predictive hospital AI system.
Deep Origin said in August 2026 that its hybrid physics-and-AI drug discovery platform achieved a 31% hit rate against a cancer immunotherapy enzyme, nearly 100 times higher than typical machine-learning-only screening approaches.
Hearing aid makers led by Starkey are adding AI-driven fall detection, activity tracking and heart rate monitoring to devices already worn all day by older adults, though researchers say real-world fall-detection accuracy still needs independent validation.
A Florida pastor is suing OpenAI, alleging ChatGPT downplayed his symptoms for months before he suffered a near-fatal pulmonary embolism, in a case testing how courts treat AI chatbots giving health-adjacent advice.
The EQUAL trial found Apple Watch-based AI heart monitoring detected atrial fibrillation in 9.6% of high-risk older adults versus 2.3% with standard care, bolstering the case for wearable-based stroke prevention.